###begin article-title 0
###xml 25 46 25 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RANTES, IL1-A, MCP-1 </italic>
###xml 50 56 50 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF-A </italic>
###xml 65 73 <span type="species:ncbi:9606">patients</span>
Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 69 74 <span type="species:ncbi:9606">human</span>
Inflammation has been implicated as an etiological factor in several human cancers, including prostate cancer. Allelic variants of the genes involved in inflammatory pathways are logical candidates as genetic determinants of prostate cancer risk. The purpose of this study was to investigate whether single nucleotide polymorphisms of genes that lead to increased levels of pro-inflammatory cytokines and chemokines are associated with an increased prostate cancer risk.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 112 117 112 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF-A</italic>
###xml 140 146 140 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RANTES</italic>
###xml 169 174 169 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1-A</italic>
###xml 200 206 200 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MCP-1 </italic>
###xml 235 243 <span type="species:ncbi:9606">patients</span>
A case-control study design was used to test the association between prostate cancer risk and the polymorphisms TNF-A-308 A/G (rs 1800629), RANTES-403 G/A (rs 2107538), IL1-A-889 C/T (rs 1800587) and MCP-1 2518 G/A (rs 1024611) in 296 patients diagnosed with prostate cancer and in 311 healthy controls from the same area.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 63 69 63 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF-A </italic>
###xml 120 127 120 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RANTES </italic>
###xml 188 194 188 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF-A </italic>
###xml 198 205 198 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RANTES </italic>
###xml 465 471 465 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1-A </italic>
###xml 474 480 474 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MCP-1 </italic>
Diagnosis of prostate cancer was significantly associated with TNF-A GA + AA genotype (OR, 1.61; 95% CI, 1.09-2.64) and RANTES GA + AA genotype (OR, 1.44; 95% CI, 1.09-2.38). A alleles in TNF-A and RANTES influenced prostate cancer susceptibility and acted independently of each other in these subjects. No epistatic effect was found for the combination of different polymorphisms studied. Finally, no overall association was found between prostate cancer risk and IL1-A or MCP-1 polymorphisms.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
Our results and previously published findings on genes associated with innate immunity support the hypothesis that polymorphisms in proinflammatory genes may be important in prostate cancer development.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 214 215 214 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 216 217 216 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 303 304 303 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 305 306 305 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 434 435 434 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 436 437 436 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 565 567 565 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 568 570 568 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 920 921 920 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 1403 1405 1403 1405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1607 1609 1607 1609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1610 1612 1610 1612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1838 1840 1831 1833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1941 1942 1934 1935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 1943 1944 1936 1937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1945 1946 1938 1939 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1947 1949 1940 1942 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 109 114 <span type="species:ncbi:9606">human</span>
Chronic or recurrent inflammation is known to play a causative role in the promotion and progression of many human tumours, including cancers of the liver, oesophagus, stomach, large intestine and urinary bladder [1-3]. Chronic inflammation has also been implicated in the aetiology of prostate cancer [4-7]. Prostate cancer risk has been associated with sexually transmitted infections and prostatitis in some epidemiologic studies [8,9], and its relationship with genetic polymorphisms in inflammatory cytokines has been explored in various case-control studies [10-13]. Chronic inflammation, alongside the intrinsic properties of pre-malignant cells and other determinants, may therefore be one of the driving forces of malignant transformation. Thus, numerous mediators released in dysregulated chronic inflammation have been found to promote cell growth and invasion, induce mutagenesis and increase angiogenicity [1]. By virtue of these properties, inflammatory mediators favour initiation of malignancy, and if sustained, may also promote progression. In general, many inflammatory conditions are characterized by the recruitment of inflammatory cells, predominantly macrophages, due to the wide variety of bioactive products they release. Cytokines and chemokines produced by activated innate immune cells are the most important components orchestrating the inflammatory-tumour-microenviroment [14]. Most studies have focussed on inflammatory chemokines that promote monocyte migration, primarily MCP-1 and also RANTES (regulated upon activation, normally T cell-expressed and presumably secreted) [15-17]. Full activation of NF-kappaB in inflammatory leukocytes resident in preneoplastic sites are likely to exacerbate local M1-inflammation (high TNF-A, high IL-1, high IL-12, low IL-10, low TGF-beta) and favour tumourigenesis [18]. In particular, pro-inflammatory cytokines (e.g. IL-1 and TNF), can themselves affect cancer risk [1,5,8,19].
###end p 11
###begin p 12
In the present investigation, we studied the role of several polymorphisms reported to have functional and biological relevance in the inflammatory process. The SNPs selected for study have all been found to influence the expression of their respective cytokine in vitro.
###end p 12
###begin p 13
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 334 338 334 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF </italic>
###xml 382 388 382 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF-A </italic>
###xml 410 412 410 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 464 466 464 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 490 496 490 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF-A </italic>
###xml 553 555 553 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 556 558 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
TNF is a key mediator of inflammation and may contribute to tumour initiation by stimulating production of genotoxic molecules, which can lead to DNA damage and mutations [20]. Inter-individual variations in TNF-A levels have been attributed to polymorphisms, notably the A allele at -308 (G/A) position in the promotor region of the TNF gene, which has been associated with higher TNF-A transcription levels [21] and an increased risk of several types of cancer [22]. However, findings on TNF-A polymorphisms in prostate cancer have been inconsistent [10-13]. In fact, evaluation of genetic variation in cytokines and chemokines in relation to inflammation and cancer risk is a complex task. Thus, it is important to investigate the possible role of other genes involved in the inflammation pathway that might influence prostate cancer risk.
###end p 13
###begin p 14
###xml 43 45 43 45 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 46 48 46 48 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 268 270 268 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 273 278 273 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-1 </italic>
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 347 349 347 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 358 360 358 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 375 377 375 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 388 390 388 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 405 407 405 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 434 440 434 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1 (-</italic>
###xml 521 523 521 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
Proinflammatory cytokines IL-1A and IL-1B [23,24] are also produced by monocytes, macrophages and epithelial cells and exhibit similar biological characteristics to TNF-A, including participation in host response to microbial invasion, inflammation and tissue injury [20]. IL-1 polymorphisms have also been linked to gastric [25], hepatocellular [26], lung [27], colorectal [28], vulvar [29] and ovarian [30] cancers. Allele T of the IL1 (-889 C>T) polymorphism has been associated with high production of this cytokine [31].
###end p 14
###begin p 15
###xml 67 71 67 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">via </italic>
###xml 96 98 96 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 118 125 118 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RANTES </italic>
###xml 354 356 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
RANTES chemokine is believed to play a role in antitumour immunity via immune cell recruitment [32]. Polymorphisms in RANTES have been associated with a higher risk of pancreatic cancer, supporting the hypothesis that proinflammatory gene polymorphisms, in combination with proinflammatory conditions, may influence the development of pancreatic cancer [33].
###end p 15
###begin p 16
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 342 348 342 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MCP-1 </italic>
###xml 461 463 461 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 540 546 540 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MCP-1 </italic>
###xml 571 573 571 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 286 294 <span type="species:ncbi:9606">patients</span>
Finally, MCP-1, a member of the CC chemokine family, possesses chemotactic activity for monocytes and T lymphocytes [34,35] and has been proposed to play a key role in macrophage recruitment, expression of angiogenic factors and activation of matrix metalloproteinases in breast cancer patients. Genetic variants within regulatory regions of MCP-1 that affect transcription and protein production have been correlated with the risk of breast cancer metastasis [36]. This finding is consistent with the previously reported overexpression of MCP-1 in breast cancer tissue [37].
###end p 16
###begin p 17
###xml 265 286 265 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RANTES, MCP-1, IL-1A </italic>
###xml 290 296 290 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF-A </italic>
These cytokines and chemokines were selected for our study because they are released in response to various forms of cellular stress, including inflammation and carcinogen exposure. The objective of this study was to assess the influence of genetic polymorphism of RANTES, MCP-1, IL-1A and TNF-A on the risk of prostate cancer.
###end p 17
###begin title 18
Methods
###end title 18
###begin title 19
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient samples
###end title 19
###begin p 20
###xml 414 415 410 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 799 800 793 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 298 306 <span type="species:ncbi:9606">Patients</span>
###xml 332 335 <span type="species:ncbi:9606">men</span>
###xml 446 449 <span type="species:ncbi:9606">men</span>
###xml 763 775 <span type="species:ncbi:9606">participants</span>
###xml 806 814 <span type="species:ncbi:9606">patients</span>
###xml 945 957 <span type="species:ncbi:9606">participants</span>
The study included adult males with a recent diagnosis of prostate cancer (n = 296) referred to our hospital between 2002 and 2007. Clinical diagnosis of primary adenocarcinoma of the prostate was histopathologically confirmed after abnormal serum PSA findings and/or lower urinary tract symptoms. Patients were unrelated Caucasian men with a mean age of 67.4 +/- 5.8 yrs and mean PSA level of 31.6 +/- 5.7 (Table 1). Healthy unrelated Caucasian men (n = 311) were enrolled as controls; these were recruited from among blood donors on the Spanish Bone Marrow Donor Registry of the same geographic region and with no history of prostate cancer according to Registry records. The mean of age of the controls was 44 +/- 11 yrs. The clinical characteristics of study participants are presented in Table 1. The patients were classified according to their disease progression, Gleason score and PSA level. Peripheral blood samples were drawn from all participants into tubes containing K3-EDTA. All subjects were interviewed by a researcher and signed their informed consent to participation in the study, which was approved by the Ethics Committee of our hospital.
###end p 20
###begin p 21
###xml 43 51 <span type="species:ncbi:9606">patients</span>
Clinical caracteristics of prostate cancer patients.
###end p 21
###begin title 22
DNA samples and genotyping
###end title 22
###begin p 23
###xml 692 696 689 691 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 1115 1118 1084 1087 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF</italic>
###xml 1145 1151 1114 1120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RANTES</italic>
###xml 1178 1183 1147 1152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-1A</italic>
###xml 1214 1220 1183 1189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MCP-1 </italic>
###xml 1340 1346 1309 1315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RANTES</italic>
###xml 1463 1465 1432 1434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 1471 1476 1440 1445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MCP-1</italic>
###xml 1574 1580 1543 1549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MCP-1 </italic>
###xml 1592 1594 1561 1563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1600 1605 1569 1574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1-A</italic>
###xml 1695 1701 1664 1670 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1-A </italic>
###xml 1712 1714 1681 1683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1720 1725 1689 1694 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF-A</italic>
###xml 1817 1823 1786 1792 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF-A </italic>
###xml 1835 1837 1804 1806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 72 80 <span type="species:ncbi:9606">patients</span>
Total genomic DNA was isolated from peripheral blood of prostate cancer patients and healthy controls using the QIAamp DNA Mini kit. SNPs samples were genotyped by means of a Taqman 5' allelic discrimination assay. The PCR and genotype of each sample was automatically attributed by measuring the allelic specific fluorescence on 500 PCR-REAL TIME Sequence Detection System using SDS 2.2.1 software for allelic discrimination (Applied Biosystems, Foster City, CA, USA). Single nucleotide polymorphism amplification assays were used according to the manufacturer's instructions. Briefly, 10 ng of sample DNA(1 mul) were placed in 4 mul of reaction solution containing: 2.5 mul of the 2x TaqMan(R) Universal PCR Mix (Applied Biosystems), 0.25 mul of predevel ped assay reagent from the SNP genotyping product(20x) (Applied Biosystems) containing two primers and two MGB-Taqman probes, and 1.25 mul of distilled water. Reaction conditions of the PCR were: preincubation at 50degreesC for 2 min and at 95degreesC for 10 min, followed by 40 cycles of 95degreesC, 15 s; 60degreesC, 1 min. The polymorphisms studied were: TNF-308 A/G (rs 1800629) SNP, RANTES-403 G/A (rs 2107538) SNP, IL-1A-889 C/T (rs 1800587) SNP, and MCP-1 2518 G/A (rs 1024611) SNP. We studied the polymorphism in the promoter region that affects its transcriptions. Thus, in RANTES, polymorphism A/G in region -403 of the promoter was studied; the A allele is associated with higher transcription [38]. In MCP-1, polymorphism A/G in region -2518 of the promoter was studied; the G allele produces much higher MCP-1 expression [39]. In IL1-A, polymorphism C/T in region -889 of the promoter was studied; the T allele causes higher IL1-A expression[31]. In TNF-A, polymorphism G/A of region -308 of the promoter was studied; the A allele produces higher TNF-A expression [40].
###end p 23
###begin title 24
Statistical analyses
###end title 24
###begin p 25
###xml 267 269 265 267 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 468 470 464 466 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
Data were compiled according to the genotype and allele frequencies estimated from the observed number of each specific allele. SNPs allele frequencies were tested against Hardy-Weinberg equilibrium by comparing observed with expected genotype frequencies using a chi2 test. The present study has a power higher than 95% to detect an Odds Ratio (OR) of 2 in all analyses (measured by Episheet programme). Genotype frequencies were compared in 2 x 2 tables with the chi2 test. The strength of association was estimated by calculating ORs with 95% CI and p values. Binary logistic regression analysis was used to confirm differences in SNP frequencies between cases and controls. Interaction analysis was calculated by logistic binary regression. The SPSS v.15.0 software package was used for the statistical analyses.
###end p 25
###begin title 26
Results
###end title 26
###begin p 27
###xml 111 112 111 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 427 429 427 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 682 688 682 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF-A </italic>
###xml 934 936 934 936 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 938 943 938 943 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0.017</italic>
###xml 1005 1012 1005 1012 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RANTES </italic>
###xml 1080 1082 1080 1082 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1084 1089 1084 1089 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0.039</italic>
###xml 1105 1111 1105 1111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MCP-1 </italic>
###xml 1124 1130 1124 1130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-1 A</italic>
###xml 1239 1240 1239 1240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 23 31 <span type="species:ncbi:9606">patients</span>
###xml 719 727 <span type="species:ncbi:9606">patients</span>
###xml 878 886 <span type="species:ncbi:9606">patients</span>
###xml 946 954 <span type="species:ncbi:9606">Patients</span>
The study included 296 patients recently diagnosed with prostate cancer and 311 blood donors (controls). Table 2 shows the genotype and allelic distributions of the polymorphisms in cases and controls, with estimated ORs. None of the SNP genotype frequencies deviated from Hardy-Weinberg equilibrium, and the distributions of alleles in the control group were in agreement with findings in other Spanish Caucasian populations [41]. Polymorphisms could sometimes not be genotyped because of PCR amplification problems, explaining discrepancies in the numbers of cases among groups. Associations were obtained by comparing with the control population (not age-matched). Comparison of TNF-A promoter polymorphisms between patients and controls revealed statistically significant differences in genotype distribution for locus -308, with a higher frequency of A carriers (AA/AG) in patients than in controls (OR = 1.61; 95% CI: 1.09-2.64 p = 0.017). Patients also showed a higher frequency of A allele in the RANTES -403 G/A polymorphism versus controls (OR = 1.44; 95% CI: 1.09-2.38 p = 0.039). In contrast, MCP-1 2518 G/A and IL-1 A- 889 T allele genotypes showed no significant differences between prostate cancer and control groups (Table 2), suggesting that these two genotypes may not play a role in susceptibility to prostate cancer.
###end p 27
###begin p 28
###xml 61 81 61 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1A, MCP-1, RANTES </italic>
###xml 85 91 85 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF-A </italic>
Statistical analysis of allele and genotype distributions of IL1A, MCP-1, RANTES and TNF-A polymorphisms.
###end p 28
###begin p 29
###xml 80 86 80 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1-A </italic>
###xml 96 102 96 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF-A </italic>
###xml 112 119 112 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RANTES </italic>
###xml 132 138 132 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MCP-1 </italic>
###xml 248 252 248 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1 </italic>
###xml 255 261 255 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MCP-1 </italic>
###xml 325 331 325 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF-A </italic>
###xml 334 341 334 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RANTES </italic>
###xml 413 414 413 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 452 456 452 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF </italic>
###xml 460 467 460 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RANTES </italic>
###xml 528 530 528 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 532 537 532 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0.012</italic>
###xml 570 572 570 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 574 579 574 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0.416</italic>
###xml 749 750 749 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 667 674 <span type="species:ncbi:9606">patient</span>
We stratified the data, grouping subjects according to their carrier status for IL1-A allele T, TNF-A allele A, RANTES allele A and MCP-1 allele G. In logistic regression analyses, no significant association with prostate cancer risk was found for IL1 or MCP-1 allele carrier status, but subjects with AG or AA genotypes for TNF-A or RANTES had increased prostate cancer risk versus those with GG genotype (Table 2). The combination of the A allele of TNF and RANTES markedly increased this risk (OR, 2.45; 95% CI, 1.22 - 4.94, p = 0.012), although no epistatic effect (p = 0.416) was observed between these polymorphisms. SNP genotypes were also compared within the patient group and stratified according to tumour stage and serum PSA level (Table 1) to determine whether the genotypes influenced these indicators. No significant associations were observed.
###end p 29
###begin title 30
Discussion
###end title 30
###begin p 31
###xml 228 234 228 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF-A </italic>
###xml 244 250 244 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RANTES</italic>
###xml 260 266 260 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-1A </italic>
###xml 279 285 279 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MCP-1 </italic>
###xml 332 338 332 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF-A </italic>
###xml 402 404 402 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 405 407 405 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 689 691 689 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 814 816 814 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 893 895 893 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 918 920 918 920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 978 984 978 984 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF-A </italic>
Several polymorphisms have been associated with the severity of or susceptibility to numerous inflammatory diseases. In this case-control study, we investigated the association between polymorphisms in cytokine/chemokine genes (TNF-A -308 G/A, RANTES-403 G/A, IL-1A -889 C/T and MCP-1 2518 G/A) and prostate cancer risk. Reports on TNF-A gene polymorphisms and prostate cancer have been controversial [10-13]. Our results suggest that the A allele, associated with a high production of TNF-A, is linked to an increased risk for prostate cancer. TNF-A, a major factor in the inflammation response, has been related to many types of cancer, e.g., T-cell large granular lymphocyte leukaemia [42], cholestatic liver cancer, multiple myeloma, bladder cancer, hepatocellular carcinoma, gastric cancer and breast cancer [22]. However, no association has been described with nasopharyngeal carcinoma [43] or cervix carcinoma [44]. Discrepancies in some previously published results for TNF-A gene polymorphisms in prostate cancer may be related to the modest risk found. Inflammation is a highly complex process that involves hundreds of genes. The fact that numerous gene polymorphisms contribute to the inflammatory response adds further complexity to the analysis of a specific polymorphism, because each individual gene is likely to contribute only modestly to the risk. Thus, TNF-A may interact in important ways with multiple cytokine/chemokines involved in inflammation pathways that also display genetic variation.
###end p 31
###begin p 32
###xml 160 166 160 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF-A </italic>
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 330 332 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 642 644 642 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 706 708 706 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
The discrepant results may be explained by the effects of genetic heterogeneity and different gene-environment interactions. Although the distribution of -308A TNF-A has been found to vary among control groups due to ethnic variations [44], the distribution of the allelic frequencies in our study was similar to a recent report [13]. The influence of other (non-inflammation-related) genes or environmental factors is more likely to account for differences. Thus, there is evidence that prostate cancer has a complex and multifactorial aetiology, which might explain discrepancies in the attribution of prostate cancer risk to a single SNP [45]. Furthermore, discrepant results between the NorthAmerican [13] and the present study might be influenced by differences in diet, lifestyle and NSAID use between the study populations.
###end p 32
###begin p 33
###xml 32 38 32 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NF-kB </italic>
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 180 182 180 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
In this context, differences in NF-kB polymorphism were reported between Spanish and North American groups in association with ulcerative colitis [46]. Finally, a Sweden Study [47,48] found that increased risk for this type of tumour is probably also influenced by other genes that regulate inflammation (Toll-like receptor) and modify individual susceptibility to prostate cancer. The combined effect of several polymorphism loci is likely to markedly increase the risk of prostate cancer.
###end p 33
###begin p 34
###xml 34 48 34 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">interleukin-1 </italic>
###xml 49 53 49 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1B</italic>
###xml 131 133 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 137 139 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 230 241 230 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1A, IL1B </italic>
###xml 245 249 245 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1R</italic>
###xml 281 283 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 284 286 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 382 384 382 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 523 528 523 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1A </italic>
###xml 488 491 <span type="species:ncbi:9606">men</span>
Gene-cluster polymorphisms in the interleukin-1 (IL1B) are associated with an increased risk of gastric and other types of cancer [25,30,49]. However, no associations have been found between polymorphisms in the IL1 gene cluster (IL1A, IL1B and IL1R) and ovarian or breast cancer [50,51]. Other authors reported no overall association between IL-1 polymorphisms and gastric cancer [52], and the reason for these different findings are unclear. The present case-control study in Caucasian men found no significant effect of IL1A (-889 C>T) gene polymorphisms on prostate cancer risk.
###end p 34
###begin p 35
###xml 211 218 211 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RANTES </italic>
###xml 222 228 222 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MCP-1 </italic>
###xml 277 283 277 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MCP-1 </italic>
###xml 374 381 374 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RANTES </italic>
###xml 407 409 407 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 411 417 411 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> 0.039</italic>
###xml 432 439 432 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RANTES </italic>
###xml 540 544 540 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">via </italic>
###xml 569 571 569 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 590 597 590 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RANTES </italic>
###xml 601 607 601 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF-A </italic>
###xml 704 706 704 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 741 747 741 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF-A </italic>
###xml 751 757 751 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RANTES</italic>
###xml 918 920 918 920 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 922 927 922 927 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0.012</italic>
###xml 1015 1017 1015 1017 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1019 1025 1019 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> 0.416</italic>
###xml 1759 1761 1759 1761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 1762 1764 1762 1764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 2003 2005 2003 2005 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 2099 2101 2099 2101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
Chemokines are also expressed in inflammation, attracting and recruiting populations of immune effector cells to injury or infection sites, and the relationship between prostate cancer risk and polymorphisms of RANTES and MCP-1 was investigated in this study. No link with the MCP-1 polymorphism was observed, but a significant association was found between the A allele of RANTES and prostate cancer risk (p =  0.039). Allele A in RANTES is associated with increased transcription, which is related to inflammation and antitumour immunity via immune cell recruitment [53]. The allele A of RANTES and TNF-A has been associated with pancreatitis, especially as a possible early sign of pancreatic cancer [33]. In our study, the same alleles (TNF-A and RANTES) were also associated with a higher prostate cancer risk. Interestingly, the simultaneous presence of allele A of both genes promotes a higher risk (OR = 2.45, p = 0.012) of cancer, but the interaction analysis showed no epistatic interaction between them (p =  0.416), indicating that their effects were additive. Finally, our study has some evident limitations and false positive results cannot be ruled out: thus, size of the study population is relatively small, aged-matched controls were not used and a possible bias corresponding to age cannot be excluded. However, even if we would have used a totally age-matched control subjects, our results would have been with even higher significance, because in this control group we cannot rule out a possibility that some of the younger control subjects may develop prostate cancer later in their life. In addition, there was no difference found between our control subjects and those used from our geographic area in a study of age-related diseases [54,55]. In general, we would like to comment that the influence of age on the immune gene polymorphism remains controversial. Some publications indicate that there are no differences in genotype distribution between older and younger controls [56], whereas others have reported an age-dependent difference in polymorphism of certain genes [57].
###end p 35
###begin p 36
###xml 38 45 <span type="species:ncbi:9606">patient</span>
There is a need for studies of larger patient groups, including other potential functional polymorphisms in linkage disequilibrium to determine the role of these polymorphisms in prostate cancer.
###end p 36
###begin title 37
Conclusion
###end title 37
###begin p 38
###xml 54 60 54 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF-A </italic>
###xml 64 71 64 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RANTES </italic>
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
In conclusion, our data suggest an important role for TNF-A and RANTES polymorphisms in prostate cancer, as observed in many other types of cancer. Other genetic polymorphisms involved in innate immunity and chronic inflammation have been associated with prostate cancer [48], and the present findings support the hypothesis that the inflammatory process may constitute an important step in the initiation and promotion of prostate cancer.
###end p 38
###begin title 39
Competing interests
###end title 39
###begin p 40
The authors declare that they have no competing interests.
###end p 40
###begin title 41
Authors' contributions
###end title 41
###begin p 42
PSL, JC and RC performed analyses, managed the storage of blood samples and performed genotyping. JMR and JRV performed statistical analyses and programming. JMC and MT were responsible for data collection and manuscript editing. FG and FRC conceived of the study, participated in its design and coordination and drafted the manuscript. All authors have read and approved the final manuscript
###end p 42
###begin title 43
Pre-publication history
###end title 43
###begin p 44
The pre-publication history for this paper can be accessed here:
###end p 44
###begin p 45

###end p 45
###begin title 46
Acknowledgements
###end title 46
###begin p 47
We would like to thank Ms. Anabel Rodriguez and Eva Garcia for technical assistance. This study was supported by grants from the Fondo de Investigaciones Sanitarias (FIS), Red Genomica del Cancer (RETIC RD 06/0020), Plan Andaluz de Investigacion (Group CTS 143), Consejeria Andaluz de Salud (SAS), Proyecto de Excelencia de Consejeria de Innovacion (CTS 695), Proyecto de investigacion I+D (SAF 2007-63262) in Spain; and from the Integrated European Cancer Immunotherapy project (OJ2004/C158, 518234).
###end p 47
###begin article-title 48
Inflammation and cancer
###end article-title 48
###begin article-title 49
Smoldering and polarized inflammation in the initiation and promotion of malignant disease
###end article-title 49
###begin article-title 50
Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators
###end article-title 50
###begin article-title 51
Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis
###end article-title 51
###begin article-title 52
Inflammation in prostate carcinogenesis
###end article-title 52
###begin article-title 53
Prostate cancer
###end article-title 53
###begin article-title 54
Epidemiology of inflammation and prostate cancer
###end article-title 54
###begin article-title 55
Epidemiologic association between prostatitis and prostate cancer
###end article-title 55
###begin article-title 56
Meta-analysis of measures of sexual activity and prostate cancer
###end article-title 56
###begin article-title 57
###xml 106 114 <span type="species:ncbi:9606">patients</span>
Frequent genotype changes at -308, and 488 regions of the tumor necrosis factor-alpha (TNF-alpha) gene in patients with prostate cancer
###end article-title 57
###begin article-title 58
p53 gene codon 72 polymorphism but not tumor necrosis factor-alpha gene is associated with prostate cancer
###end article-title 58
###begin article-title 59
Influence of cytokine gene polymorphisms on the development of prostate cancer
###end article-title 59
###begin article-title 60
TNF polymorphisms and prostate cancer risk
###end article-title 60
###begin article-title 61
A cytokine-mediated link between innate immunity, inflammation, and cancer
###end article-title 61
###begin article-title 62
CCL2 (monocyte chemoattractant protein-1) and cancer
###end article-title 62
###begin article-title 63
###xml 110 115 <span type="species:ncbi:9606">human</span>
Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer
###end article-title 63
###begin article-title 64
The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity
###end article-title 64
###begin article-title 65
Cancer related inflammation: The macrophage connection
###end article-title 65
###begin article-title 66
Inflammation in prostate carcinogenesis
###end article-title 66
###begin article-title 67
Radical causes of cancer
###end article-title 67
###begin article-title 68
###xml 33 38 <span type="species:ncbi:9606">human</span>
Effects of a polymorphism in the human tumor necrosis factor a promoter on transcriptional activation
###end article-title 68
###begin article-title 69
Tumor necrosis factor, cancer and anticancer therapy
###end article-title 69
###begin article-title 70
The interleukin-1 family: 10 years of discovery
###end article-title 70
###begin article-title 71
Interleukin 1 receptor antagonist. A new member of the interleukin 1 family
###end article-title 71
###begin article-title 72
Interleukin-1 polymorphisms associated with increased risk of gastric cancer
###end article-title 72
###begin article-title 73
###xml 81 98 <span type="species:ncbi:11103">hepatitis C virus</span>
Interleukin-1beta gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection
###end article-title 73
###begin article-title 74
Polymorphisms of the interleukin-1beta gene are associated with increased risk of non-small cell lung cancer
###end article-title 74
###begin article-title 75
Association of common polymorphisms in inflammatory genes interleukin IL6, IL8, tumor necrosis factor-a, NFK B1, andperoxisome proliferator-activated receptor g with colorectal cancer
###end article-title 75
###begin article-title 76
A polymorphism of the interleukin-1 receptor antagonist plays a prominent role within the interleukin-1 gene cluster in vulvar carcinogenesis
###end article-title 76
###begin article-title 77
Interleukin-1 receptor antagonist gene polymorphism is associated with increased risk of epithelial ovarian cancer
###end article-title 77
###begin article-title 78
Cloning and functional analysis of the allelic polymorphism in the transcription regulatory region of interleukin-1 alpha
###end article-title 78
###begin article-title 79
RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations
###end article-title 79
###begin article-title 80
Inflammation, genetic polymorphisms in proinflammatory genes TNF-A, RANTES, and CCR5, and risk of pancreatic adenocarcinoma
###end article-title 80
###begin article-title 81
###xml 44 49 <span type="species:ncbi:9606">human</span>
Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants
###end article-title 81
###begin article-title 82
C-C chemokines, but not the C-X-C chemokines interleukin-8 and interferon-gamma inducible protein-10, stimulate transendothelial chemotaxis of T lymphocytes
###end article-title 82
###begin article-title 83
Breast cancer progression and host polymorphisms in the chemokine system: role of the macrophage chemoattractant protein-1 (MCP-1) -2518 G allele
###end article-title 83
###begin article-title 84
Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma
###end article-title 84
###begin article-title 85
###xml 50 55 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression
###end article-title 85
###begin article-title 86
A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression
###end article-title 86
###begin article-title 87
###xml 33 38 <span type="species:ncbi:9606">human</span>
Effects of a polymorphism in the human tumor necrosis factor a promoter on transcriptional activation
###end article-title 87
###begin article-title 88
Tumor necrosis factor gene polymorphisms in ankylosing spondylitis
###end article-title 88
###begin article-title 89
Immunogenetic factors determining the evolution of T-cell large granular lymphocyte leukaemia and associated cytopenias
###end article-title 89
###begin article-title 90
Evaluation of the associations between the single nucleotide polymorphisms of the promoter region of the tumor necrosis factor-alpha gene and nasopharyngeal carcinoma
###end article-title 90
###begin article-title 91
###xml 96 101 <span type="species:ncbi:9606">women</span>
###xml 135 140 <span type="species:ncbi:9606">women</span>
The allelic distribution of -308 Tumor Necrosis Factor-alpha gene polymorphism in South African women with cervical cancer and control women
###end article-title 91
###begin article-title 92
Complexities of prostate-cancer risk
###end article-title 92
###begin article-title 93
A functional polymorphism of the NFKB1 promoter is not associated with ulcerative colitis in a Spanish population
###end article-title 93
###begin article-title 94
###xml 54 59 54 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR6 </italic>
###xml 60 64 60 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR1</italic>
###xml 65 70 65 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TLR10</italic>
Sequence variants in Toll-like receptor gene cluster (TLR6 -TLR1-TLR10) and prostate cancer risk
###end article-title 94
###begin article-title 95
Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the Cancer Prostate in Sweden Study
###end article-title 95
###begin article-title 96
Interleukin-1 polymorphisms associated with increased risk of gastric cancer
###end article-title 96
###begin article-title 97
Polymorphisms of the interleukin-1 gene cluster and ovarian cancer
###end article-title 97
###begin article-title 98
###xml 94 99 <span type="species:ncbi:9606">women</span>
Interleukin-1 and interleukin-6 gene polymorphisms and the risk of breast cancer in caucasian women
###end article-title 98
###begin article-title 99
Interleukin-1B polymorphisms and gastric cancer risk-a meta-analysis
###end article-title 99
###begin article-title 100
Rantes secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations
###end article-title 100
###begin article-title 101
Association study of genetic variants of pro-inflammatory chemokine and cytokine genes in systemic lupus erythematosus
###end article-title 101
###begin article-title 102
Polymorphism at the TNF loci in rheumatoid arthritis
###end article-title 102
###begin article-title 103
###xml 84 87 <span type="species:ncbi:9606">men</span>
Inflammation, genetics, and longevity: further studies on the protective effects in men of IL-10 -1082 promoter SNP and its interaction with TNF-alpha -308 promoter SNP
###end article-title 103
###begin article-title 104
A genetic-demographic approach reveals male-specific association between survival and tumor necrosis factor (A/G)-308 polymorphism
###end article-title 104

